A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors
This important study is testing a medicine called emicizumab in very young children, from newborns up to 12 months of age, who have severe haemophilia A. Haemophilia A is a condition where blood doesn't clot properly, leading to bleeding. Emicizumab is designed to help blood clot and reduce bleeding episodes. The study wants to find out how effective this medicine is, if it's safe for babies, and how their bodies react to it. Participants will receive the medicine for a year, and then continue to be followed for several more years to see its long-term effects. This research could help improve treatments for babies born with this condition.
De un vistazo
Resultados
Resultados de este estudio
Publicado June 2024Se han publicado los resultados de este estudio.
¿De qué trata este estudio?
This study is focusing on a new way to help babies with severe haemophilia A, a condition that makes them bleed easily. Normally, our blood contains a protein called Factor VIII that helps it clot. In people with severe haemophilia A, there isn't enough of this protein, making them at risk of bleeding into joints, muscles, or even the brain. This study is testing a medicine called emicizumab, which works differently from traditional treatments by helping the blood clotting process happen more easily.
The main goal is to understand if emicizumab is a safe and effective treatment for these very young patients. Researchers will be looking at how well it prevents bleeding episodes, how the babies' bodies handle the medicine, and if there are any side effects. This is a "Phase IIIb" study, which means it's one of the final stages of testing a new medicine before it might be available more widely. The study will last for a year, with participants receiving the medicine regularly, followed by a longer period of up to seven years to see the long-term benefits and safety.
Developing new treatments for babies is crucial because they are at a vulnerable stage, and preventing early bleeds can make a big difference to their health as they grow. This research aims to provide valuable information that could help doctors choose the best care for infants with severe haemophilia A, potentially improving their quality of life by reducing bleeding complications.
Puntos clave
- This study is for babies with severe haemophilia A, from birth up to 12 months old.
- It tests a medicine called emicizumab to prevent bleeding.
- The treatment involves regular injections under the skin.
- The study includes a one-year treatment phase followed by up to seven years of monitoring.
- Regular clinic visits and blood tests are required to monitor health and treatment effectiveness.
¿Quién puede ser elegible?
This study is looking for very specific patients. It's for babies who are newborn up to 12 months old when they join, and they must weigh at least 3 kilograms (about 6.6 pounds). They need to have been diagnosed with severe haemophilia A, meaning their bodies produce very little of the important Factor VIII protein. It's also important that they haven't developed 'inhibitors' – these are like antibodies that can stop standard Factor VIII treatments from working.
The study is for babies who haven't had much previous treatment for their haemophilia. This means they should either be completely new to treatment or have only had very limited exposure (up to 5 days) to haemophilia medicines. Babies with other bleeding disorders or those who have had certain other medications are not able to join. All parents or caregivers must be willing and able to follow the study's requirements closely.
¿Podría este estudio ser adecuado para ti?
Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.
- Is your baby 12 months old or younger?
- Does your baby weigh at least 3 kilograms (about 6.6 pounds)?
- Has your baby been diagnosed with severe haemophilia A?
- Has your baby received very little or no previous haemophilia treatment?
- Do you have a clear understanding of the study requirements and feel able to commit to them?
¿En qué consiste la participación?
If your baby takes part in this study, they will receive the study medicine, emicizumab, as an injection under the skin every two weeks for the first year. After this first year, they will continue to receive the medicine, but the dose and how often it's given might change (either weekly, every two weeks, or every four weeks) for up to an additional seven years. This means the study could last for a total of eight years.
Throughout the study, your baby will have regular visits to the clinic. At these visits, doctors will check their health, do blood tests to see how the medicine is working and to monitor for any side effects, and track any bleeding episodes. You will also be asked to fill out questionnaires. It's important to attend all scheduled appointments and follow the doctor's instructions carefully.
Riesgos y beneficios potenciales
Locations (32)
- Phoenix Children's HospitalCódigo postal verificadoPhoenix, Estados Unidos
- Children's Hospital Los AngelesCódigo postal verificadoLos Angeles, United States
- University of Colorado Denver, Children's HospitalCódigo postal verificadoAurora, Estados Unidos
- Tulane University Health Sciences CenterCódigo postal verificadoNew Orleans, United States
- University of MichiganCódigo postal verificadoAnn Arbor, Estados Unidos
- Seattle Children's HospitalCódigo postal verificadoSeattle, United States
- The Children's Hospital at WestmeadCódigo postal verificadoWestmead, Australia
- Royal Children's HospitalCódigo postal verificadoParkville, Australia
- Perth Children's HospitalCódigo postal verificadoNedlands, Australia
- Medizinische Universität WienCódigo postal verificadoViena, Austria
- Cliniques Universitaires St-LucCódigo postal verificadoBruselas, Bélgica
- UZ Leuven GasthuisbergCódigo postal verificadoLovaina, Bélgica
Preguntas comunes
What is haemophilia A?
Haemophilia A is a genetic condition where a person's blood doesn't clot properly because they don't have enough of a protein called Factor VIII, leading to easy bleeding.
What is emicizumab?
Emicizumab is a medicine designed to help the blood clotting process in people with haemophilia A, aiming to reduce the number of bleeding episodes.
How will my baby receive the medicine?
The medicine, emicizumab, will be given to your baby as an injection just under the skin, similar to a regular jab.
¿Cuánto tiempo durará el estudio?
The initial treatment period is for one year, but participants will then be followed for up to an additional seven years, making the total study duration up to eight years.
Can we stop participating at any time?
Yes, you have the right to withdraw your baby from the study at any point, and this will not affect their regular medical care.
Cómo obtener más información
Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.
Discusión
Discusión comunitaria
Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.